Ondrey Aaron
Known title: Chief Financial OfficerCIK: 0001991078
Associated companies
Transaction History
| RCKT | ▼ Sell | Open Market | 1,477 | $4K | 7/3/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 7,489 | $40K | 4/4/2025 | View on chart |
| RCKT | ▲ Buy | Grant | 90,358 | $0 | 2/11/2025 | View on chart |
| RCKT | ▲ Buy | Grant | 46,781 | $0 | 4/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial
Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial. Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.